Immunology of Toxoplasma gondii

Immunological Reviews

Volumn 240, Issue 1, 2011, Pages 269-285

  Munoz, Melba ^a   Liesenfeld, Oliver ^a   Heimesaat, Markus M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytokines; Infectious diseases; Inflammation; Parasitic infection

Indexed keywords

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; CONGENITAL TOXOPLASMOSIS; DISEASE MODEL; ENTERITIS; EXPERIMENTAL MODEL; GRANULOCYTE; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOLOGY; MACROPHAGE; MOUTH INFECTION; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NONHUMAN; PARASITE TRANSMISSION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYMPTOM; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; TOXOPLASMA; TOXOPLASMOSIS;

EID: 79951886883     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00992.x     Document Type: Review

References (155)

1. Barragan A, Sibley LD. Transepithelial migration of Toxoplasma gondii is linked to parasite motility and virulence. J Exp Med 2002;195:1625-1633.
2. Black MW, Boothroyd JC. Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev 2000;64:607-623.
3. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:1643-1648.
4. Dubey JP, Miller NL, Frenkel JK. The Toxoplasma gondii oocyst from cat feces. J Exp Med 1970;132:636-662.
5. Luft BJ, et al. Outbreak of central-nervous-system toxoplasmosis in western Europe and North America. Lancet 1983;1:781-784.
6. Wong B. Parasitic diseases in immunocompromised hosts. Am J Med 1984;76:479-486.
7. Vaudaux JD, et al. Identification of an atypical strain of Toxoplasma gondii as the cause of a waterborne outbreak of toxoplasmosis in Santa Isabel do Ivai, Brazil. J Infect Dis 2010;202:1226-1233.
8. Conrad PA, et al. Transmission of Toxoplasma: clues from the study of sea otters as sentinels of Toxoplasma gondii flow into the marine environment. Int J Parasitol 2005;35:1155-1168.
9. Miller MA, et al. An unusual genotype of Toxoplasma gondii is common in California sea otters (Enhydra lutris nereis) and is a cause of mortality. Int J Parasitol 2004;34:275-284.
10. Sibley LD, Boothroyd JC. Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature 1992;359:82-85.
11. Dubey JP. Long-term persistence of Toxoplasma gondii in tissues of pigs inoculated with T. gondii oocysts and effect of freezing on viability of tissue cysts in pork. Am J Vet Res 1988;49:910-913.
12. Siegel SE, et al. Transmission of toxoplasmosis by leukocyte transfusion. Blood 1971;37:388-394.
13. Dubey JP, Jones JL. Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol 2008;38:1257-1278.
14. Guerina NG, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1858-1863.
15. Desmonts G, Couvreur J. Congenital toxoplasmosis. A prospective study of 378 pregnancies. N Engl J Med 1974;290:1110-1116.
16. Holliman RE. Congenital toxoplasmosis: prevention, screening and treatment. J Hosp Infect 1995;30(Suppl):179-190.
17. McAuley J, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994;18:38-72.
18. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980;66:767-774.
19. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15:211-222.
20. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 2001;154:357-365.
21. Liesenfeld O. Immune responses to Toxoplasma gondii in the gut. Immunobiology 1999;201:229-239.
22. Nutter FB, Dubey JP, Levine JF, Breitschwerdt EB, Ford RB, Stoskopf MK. Seroprevalences of antibodies against Bartonella henselae and Toxoplasma gondii and fecal shedding of Cryptosporidium spp, Giardia spp, and Toxocara cati in feral and pet domestic cats. J Am Vet Med Assoc 2004;225:1394-1398.
23. Elmore SA, Jones JL, Conrad PA, Patton S, Lindsay DS, Dubey JP. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol 2010;26:190-196.
24. Vollaire MR, Radecki SV, Lappin MR. Seroprevalence of Toxoplasma gondii antibodies in clinically ill cats in the United States. Am J Vet Res 2005;66:874-877.
25. Dubey JP, Leighty JC, Beal VC, Anderson WR, Andrews CD, Thulliez P. National seroprevalence of Toxoplasma gondii in pigs. J Parasitol 1991;77:517-521.
26. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004;363:1965-1976.
27. Carme B, et al. Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. J Clin Microbiol 2002;40:4037-4044.
28. Demar M, et al. Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspects. Clin Infect Dis 2007;45:e88-e95.
29. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 2003;136:973-988.
30. Leport C, Derouin F, Morlat P, Chene G, Vilde JL. (Toxoplasmosis in immunosuppressed patients. Contribution to the knowledge of toxoplasmic infection.). Med Mal Infect 1996;26(Suppl):437-440.
31. Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation 2009;16:122-133.
32. Carruthers VB, Sibley LD. Sequential protein secretion from three distinct organelles of Toxoplasma gondii accompanies invasion of human fibroblasts. Eur J Cell Biol 1997;73:114-123.
33. Dubremetz JF, Achbarou A, Bermudes D, Joiner KA. Kinetics and pattern of organelle exocytosis during Toxoplasma gondii/host-cell interaction. Parasitol Res 1993;79:402-408.
34. Saeij JP, Coller S, Boyle JP, Jerome ME, White MW, Boothroyd JC. Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature 2007;445:324-327.
35. Saeij JP, et al. Polymorphic secreted kinases are key virulence factors in toxoplasmosis. Science 2006;314:1780-1783.
36. Taylor S, et al. A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science 2006;314:1776-1780.
37. Blanchard N, et al. Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum. Nat Immunol 2008;9:937-944.
38. Barragan A, Brossier F, Sibley LD. Transepithelial migration of Toxoplasma gondii involves an interaction of intercellular adhesion molecule 1 (ICAM-1) with the parasite adhesin MIC2. Cell Microbiol 2005;7:561-568.
39. Debierre-Grockiego F, et al. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii. J Immunol 2007;179:1129-1137.
40. Fang H, et al. Toxoplasma gondii-derived heat shock protein 70 induces lethal anaphylactic reaction through activation of cytosolic phospholipase A2 and platelet-activating factor via Toll-like receptor 4/myeloid differentiation factor 88. Microbiol Immunol 2008;52:366-374.
41. Yarovinsky F, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005;308:1626-1629.
42. Yarovinsky F. Toll-like receptors and their role in host resistance to Toxoplasma gondii. Immunol Lett 2008;119:17-21.
43. Egan CE, Sukhumavasi W, Butcher BA, Denkers EY. Functional aspects of Toll-like receptor/MyD88 signalling during protozoan infection: focus on Toxoplasma gondii. Clin Exp Immunol 2009;156:17-24.
44. Butcher BA, Denkers EY. Mechanism of entry determines the ability of Toxoplasma gondii to inhibit macrophage proinflammatory cytokine production. Infect Immun 2002;70:5216-5224.
45. Dobbin CA, Smith NC, Johnson AM. Heat shock protein 70 is a potential virulence factor in murine Toxoplasma infection via immunomodulation of host NF-kappa B and nitric oxide. J Immunol 2002;169:958-965.
46. Ahmed AK, et al. Roles of Toxoplasma gondii-derived heat shock protein 70 in host defense against T. gondii infection. Microbiol Immunol 2004;48:911-915.
47. Shapira S, Speirs K, Gerstein A, Caamano J, Hunter CA. Suppression of NF-kappaB activation by infection with Toxoplasma gondii. J Infect Dis 2002;185(Suppl):S66-S72.
48. Kim L, et al. p38 MAPK autophosphorylation drives macrophage IL-12 production during intracellular infection. J Immunol 2005;174:4178-4184.
49. Kim SK, Fouts AE, Boothroyd JC. Toxoplasma gondii dysregulates IFN-gamma-inducible gene expression in human fibroblasts: insights from a genome-wide transcriptional profiling. J Immunol 2007;178:5154-5165.
50. Lang C, Algner M, Beinert N, Gross U, Luder CG. Diverse mechanisms employed by Toxoplasma gondii to inhibit IFN-gamma-induced major histocompatibility complex class II gene expression. Microbes Infect 2006;8:1994-2005.
51. Butcher BA, Kim L, Panopoulos AD, Watowich SS, Murray PJ, Denkers EY. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-alpha in host macrophages. J Immunol 2005;174:3148-3152.
52. Kafsack BF, Pena JD, Coppens I, Ravindran S, Boothroyd JC, Carruthers VB. Rapid membrane disruption by a perforin-like protein facilitates parasite exit from host cells. Science 2009;323:530-533.
53. Carmen JC, Sinai AP. Suicide prevention: disruption of apoptotic pathways by protozoan parasites. Mol Microbiol 2007;64:904-916.
54. Luder CG, Gross U. Apoptosis and its modulation during infection with Toxoplasma gondii: molecular mechanisms and role in pathogenesis. Curr Top Microbiol Immunol 2005;289:219-237.
55. Suzuki Y, Remington JS. Toxoplasmic encephalitis in AIDS patients and experimental models for study of the disease and its treatment. Res Immunol 1993;144:66-67.
56. Sumyuen MH, Garin YJ, Derouin F. Effect of immunosuppressive drug regimens on acute and chronic murine toxoplasmosis. Parasitol Res 1996;82:681-686.
57. Gazzinelli RT, Eltoum I, Wynn TA, Sher A. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J Immunol 1993;151:3672-3681.
58. Gazzinelli R, Xu Y, Hieny S, Cheever A, Sher A. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J Immunol 1992;149:175-180.
59. Dunay IR, et al. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2004;48:4848-4854.
60. Jost C, Reiter-Owona I, Liesenfeld O. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice. Parasitol Res 2007;101:1603-1609.
61. Gazzinelli RT, Brezin A, Li Q, Nussenblatt RB, Chan CC. Toxoplasma gondii: acquired ocular toxoplasmosis in the murine model, protective role of TNF-alpha and IFN-gamma. Exp Parasitol 1994;78:217-229.
62. Lu F, Huang S, Hu MS, Kasper LH. Experimental ocular toxoplasmosis in genetically susceptible and resistant mice. Infect Immun 2005;73:5160-5165.
63. Lu F, Huang S, Kasper LH. CD4+ T cells in the pathogenesis of murine ocular toxoplasmosis. Infect Immun 2004;72:4966-4972.
64. Jones LA, Alexander J, Roberts CW. Ocular toxoplasmosis: in the storm of the eye. Parasite Immunol 2006;28:635-642.
65. Pfaff AW, et al. Cellular and molecular physiopathology of congenital toxoplasmosis: the dual role of IFN-gamma. Parasitology 2007;134:1895-1902.
66. McLeod R, Skamene E, Brown CR, Eisenhauer PB, Mack DG. Genetic regulation of early survival and cyst number after peroral Toxoplasma gondii infection of A×B/B×A recombinant inbred and B10 congenic mice. J Immunol 1989;143:3031-3034.
67. Liesenfeld O, Kosek J, Remington JS, Suzuki Y. Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med 1996;184:597-607.
68. Liesenfeld O. Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease? J Infect Dis 2002;185(Suppl):S96-S101.
69. Hermes G, et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation 2008;5:48.
70. Buzoni-Gatel D, Schulthess J, Menard LC, Kasper LH. Mucosal defences against orally acquired protozoan parasites, emphasis on Toxoplasma gondii infections. Cell Microbiol 2006;8:535-544.
71. Del Rio L, Bennouna S, Salinas J, Denkers EY. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J Immunol 2001;167:6503-6509.
72. Khan IA, et al. Mice lacking the chemokine receptor CCR1 show increased susceptibility to Toxoplasma gondii infection. J Immunol 2001;166:1930-1937.
73. Bliss SK, Gavrilescu LC, Alcaraz A, Denkers EY. Neutrophil depletion during Toxoplasma gondii infection leads to impaired immunity and lethal systemic pathology. Infect Immun 2001;69:4898-4905.
74. Dunay IR, Sibley LD. Monocytes mediate mucosal immunity to Toxoplasma gondii. Curr Opin Immunol 2010;22:461-466.
75. Dunay IR, Fuchs A, Sibley LD. Inflammatory monocytes but not neutrophils are necessary to control infection with Toxoplasma gondii in mice. Infect Immun 2010;78:1564-1570.
76. Scott P, Hunter CA. Dendritic cells and immunity to leishmaniasis and toxoplasmosis. Curr Opin Immunol 2002;14:466-470.
77. Liu CH, et al. Cutting edge: dendritic cells are essential for in vivo IL-12 production and development of resistance against Toxoplasma gondii infection in mice. J Immunol 2006;177:31-35.
78. Channon JY, Seguin RM, Kasper LH. Differential infectivity and division of Toxoplasma gondii in human peripheral blood leukocytes. Infect Immun 2000;68:4822-4826.
79. Lambert H, Hitziger N, Dellacasa I, Svensson M, Barragan A. Induction of dendritic cell migration upon Toxoplasma gondii infection potentiates parasite dissemination. Cell Microbiol 2006;8:1611-1623.
80. Lambert H, Vutova PP, Adams WC, Lore K, Barragan A. The Toxoplasma gondii-shuttling function of dendritic cells is linked to the parasite genotype. Infect Immun 2009;77:1679-1688.
81. Tait ED, et al. Virulence of Toxoplasma gondii is associated with distinct dendritic cell responses and reduced numbers of activated CD8+ T cells. J Immunol 2010;185:1502-1512.
82. Sher A, Oswald IP, Hieny S, Gazzinelli RT. Toxoplasma gondii induces a T-independent IFN-gamma response in natural killer cells that requires both adherent accessory cells and tumor necrosis factor-alpha. J Immunol 1993;150:3982-3989.
83. Gazzinelli RT, Denkers EY, Sher A. Host resistance to Toxoplasma gondii: model for studying the selective induction of cell-mediated immunity by intracellular parasites. Infect Agents Dis 1993;2:139-149.
84. Gazzinelli RT, et al. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol 1994;153:2533-2543.
85. Hunter CA, Candolfi E, Subauste C, Van Cleave V, Remington JS. Studies on the role of interleukin-12 in acute murine toxoplasmosis. Immunology 1995;84:16-20.
86. Scanga CA, et al. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 2002;168:5997-6001.
87. Martens S, et al. Disruption of Toxoplasma gondii parasitophorous vacuoles by the mouse p47-resistance GTPases. PLoS Pathog 2005;1:e24.
88. Howard J. The IRG proteins: a function in search of a mechanism. Immunobiology 2008;213:367-375.
89. Hisaeda H, Sakai T, Maekawa Y, Ishikawa H, Yasutomo K, Himeno K. Mechanisms of HSP65 expression induced by gamma delta T cells in murine Toxoplasma gondii infection. Pathobiology 1996;64:198-203.
90. Bohne W, Heesemann J, Gross U. Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in triggering stage conversion. Infect Immun 1994;62:1761-1767.
91. Khan IA, Schwartzman JD, Matsuura T, Kasper LH. A dichotomous role for nitric oxide during acute Toxoplasma gondii infection in mice. Proc Natl Acad Sci USA 1997;94:13955-13960.
92. French AR, Holroyd EB, Yang L, Kim S, Yokoyama WM. IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine 2006;35:229-234.
93. Khan IA, et al. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog 2006;2:e49.
94. Guan H, Moretto M, Bzik DJ, Gigley J, Khan IA. NK cells enhance dendritic cell response against parasite antigens via NKG2D pathway. J Immunol 2007;179:590-596.
95. Lindberg RE, et al. IFN-gamma-induced l-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha. J Immunol 1992;148:568-574.
96. Langermans JA, et al. IFN-gamma-induced l-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha. J Immunol 1992;148:568-574.
97. Sibley LD, Adams LB, Fukutomi Y, Krahenbuhl JL. Tumor necrosis factor-alpha triggers antitoxoplasmal activity of IFN-gamma primed macrophages. J Immunol 1991;147:2340-2345.
98. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 1988;240:516-518.
99. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 1991;146:286-292.
100. Brown CR, et al. Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology 1995;85:419-428.
101. Gazzinelli RT, Oswald IP, James SL, Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J Immunol 1992;148:1792-1796.
102. Shaw MH, et al. T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat Immunol 2009;10:1267-1274.
103. Chardes T, Buzoni-Gatel D, Lepage A, Bernard F, Bout D. Toxoplasma gondii oral infection induces specific cytotoxic CD8 alpha/beta+ Thy-1+ gut intraepithelial lymphocytes, lytic for parasite-infected enterocytes. J Immunol 1994;153:4596-4603.
104. Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun 2000;68:1026-1033.
105. Mack DG, McLeod R. Human Toxoplasma gondii-specific secretory immunoglobulin A reduces T. gondii infection of enterocytes in vitro. J Clin Invest 1992;90:2585-2592.
106. Couper KN, Roberts CW, Brombacher F, Alexander J, Johnson LL. Toxoplasma gondii-specific immunoglobulin M limits parasite dissemination by preventing host cell invasion. Infect Immun 2005;73:8060-8068.
107. Gazzinelli RT, Amichay D, Sharton-Kersten T, Grunwald E, Farber JM, Sher A. Role of macrophage-derived cytokines in the induction and regulation of cell-mediated immunity to Toxoplasma gondii. Curr Top Microbiol Immunol 1996;219:127-139.
108. Khan IA, Matsuura T, Kasper LH. IL-10 mediates immunosuppression following primary infection with Toxoplasma gondii in mice. Parasite Immunol 1995;17:185-195.
109. Langermans JA, Nibbering PH, Van Vuren-Van Der Hulst ME, Van Furth R. Transforming growth factor-beta suppresses interferon-gamma-induced toxoplasmastatic activity in murine macrophages by inhibition of tumour necrosis factor-alpha production. Parasite Immunol 2001;23:169-175.
110. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-3822.
111. Hunter CA, Bermudez L, Beernink H, Waegell W, Remington JS. Transforming growth factor-beta inhibits interleukin-12-induced production of interferon-gamma by natural killer cells: a role for transforming growth factor-beta in the regulation of T cell-independent resistance to Toxoplasma gondii. Eur J Immunol 1995;25:994-1000.
112. Oldenhove G, et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009;31:772-786.
113. Aliberti J, Serhan C, Sher A. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 2002;196:1253-1262.
114. Butcher BA, Kim L, Johnson PF, Denkers EY. Toxoplasma gondii tachyzoites inhibit proinflammatory cytokine induction in infected macrophages by preventing nuclear translocation of the transcription factor NF-kappa B. J Immunol 2001;167:2193-2201.
115. Luder CG, Lang T, Beuerle B, Gross U. Down-regulation of MHC class II molecules and inability to up-regulate class I molecules in murine macrophages after infection with Toxoplasma gondii. Clin Exp Immunol 1998;112:308-316.
116. Luder CG, Seeber F. Toxoplasma gondii and MHC-restricted antigen presentation: on degradation, transport and modulation. Int J Parasitol 2001;31:1355-1369.
117. Lang C, Gross U, Luder CG. Subversion of innate and adaptive immune responses by Toxoplasma gondii. Parasitol Res 2007;100:191-203.
118. Seabra SH, de Souza W, DaMatta RA. Toxoplasma gondii partially inhibits nitric oxide production of activated murine macrophages. Exp Parasitol 2002;100:62-70.
119. Liesenfeld O, Dunay IR, Erb KJ. Infection with Toxoplasma gondii reduces established and developing Th2 responses induced by Nippostrongylus brasiliensis infection. Infect Immun 2004;72:3812-3822.
120. Santiago HC, et al. Coinfection with Toxoplasma gondii inhibits antigen-specific Th2 immune responses, tissue inflammation, and parasitism in BALB/c mice infected with Leishmania major. Infect Immun 1999;67:4939-4944.
121. Ruskin J, Remington JS. Immunity and intracellular infection: resistance to bacteria in mice infected with a protozoan. Science 1968;160:72-74.
122. Remington JS, Merigan TC. Resistance to virus challenge in mice infected with protozoa or bacteria. Proc Soc Exp Biol Med 1969;131:1184-1188.
123. Gentry LO, Remington JS. Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J Infect Dis 1971;123:22-31.
124. Mengs U, Pelster B. The course of Plasmodium berghei infection in mice latently infected with Toxoplasma gondii. Experientia 1982;38:570-571.
125. Mahmoud AA, Warren KS, Strickland GT. Acquired resistance to infection with Schistosoma mansoni induced by Toxoplasma gondii. Nature 1976;263:56-57.
126. Khan IA, Hakak R, Eberle K, Sayles P, Weiss LM, Urban JF Jr. Coinfection with Heligmosomoides polygyrus fails to establish CD8+ T-cell immunity against Toxoplasma gondii. Infect Immun 2008;76:1305-1313.
127. Marshall AJ, et al. Toxoplasma gondii and Schistosoma mansoni synergize to promote hepatocyte dysfunction associated with high levels of plasma TNF-alpha and early death in C57BL/6 mice. J Immunol 1999;163:2089-2097.
128. Miller L, Alley EW, Murphy WJ, Russell SW, Hunt JS. Progesterone inhibits inducible nitric oxide synthase gene expression and nitric oxide production in murine macrophages. J Leukoc Biol 1996;59:442-450.
129. Huck B, Steck T, Habersack M, Dietl J, Kammerer U. Pregnancy associated hormones modulate the cytokine production but not the phenotype of PBMC-derived human dendritic cells. Eur J Obstet Gynecol Reprod Biol 2005;122:85-94.
130. Abou-Bacar A, et al. Role of NK cells and gamma interferon in transplacental passage of Toxoplasma gondii in a mouse model of primary infection. Infect Immun 2004;72:1397-1401.
131. Suzuki Y. Host resistance in the brain against Toxoplasma gondii. J Infect Dis 2002;185(Suppl):S58-S65.
132. Stumhofer JS, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006;7:937-945.
133. Drogemuller K, et al. Astrocyte gp130 expression is critical for the control of Toxoplasma encephalitis. J Immunol 2008;181:2683-2693.
134. Wilson AA, et al. Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest 2010;120:379-389.
135. Schreiner M, Liesenfeld O. Small intestinal inflammation following oral infection with Toxoplasma gondii does not occur exclusively in C57BL/6 mice: review of 70 reports from the literature. Mem Inst Oswaldo Cruz 2009;104:221-233.
136. Heimesaat MM, et al. Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii. J Immunol 2006;177:8785-8795.
137. Denkers EY. A gut feeling for microbes: getting it going between a parasite and its host. Cell Host Microbe 2009;6:104-106.
138. Heimesaat MM, et al. Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut 2007;56:941-948.
139. Erridge C, Duncan SH, Bereswill S, Heimesaat MM. The induction of colitis and ileitis in mice is associated with marked increases in intestinal concentrations of stimulants of TLRs 2, 4, and 5. PLoS ONE 2010;5:e9125.
140. Dunay IR, et al. Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 2008;29:306-317.
141. Chardes T, Bout D. Mucosal immune response in toxoplasmosis. Res Immunol 1993;144:57-60.
142. Kasper LH, Matsuura T, Fonseka S, Arruda J, Channon JY, Khan IA. Induction of gammadelta T cells during acute murine infection with Toxoplasma gondii. J Immunol 1996;157:5521-5527.
143. Mennechet FJ, Kasper LH, Rachinel N, Li W, Vandewalle A, Buzoni-Gatel D. Lamina propria CD4+ T lymphocytes synergize with murine intestinal epithelial cells to enhance proinflammatory response against an intracellular pathogen. J Immunol 2002;168:2988-2996.
144. Egan CE, Craven MD, Leng J, Mack M, Simpson KW, Denkers EY. CCR2-dependent intraepithelial lymphocytes mediate inflammatory gut pathology during Toxoplasma gondii infection. Mucosal Immunol 2009;2:527-535.
145. Vossenkamper A, et al. Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Eur J Immunol 2004;34:3197-3207.
146. Munoz M, et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 2009;206:3047-3059.
147. Guiton R, et al. Interleukin 17 receptor signaling is deleterious during Toxoplasma gondii infection in susceptible BL6 mice. J Infect Dis 2010;202:427-435.
148. Kelly MN, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 2005;73:617-621.
149. Buzoni-Gatel D, et al. Murine ileitis after intracellular parasite infection is controlled by TGF-beta-producing intraepithelial lymphocytes. Gastroenterology 2001;120:914-924.
150. Mennechet FJ, et al. Intestinal intraepithelial lymphocytes prevent pathogen-driven inflammation and regulate the Smad/T-bet pathway of lamina propria CD4+ T cells. Eur J Immunol 2004;34:1059-1067.
151. Suzuki Y, et al. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J Immunol 2000;164:5375-5382.
152. Jankovic D, et al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 2007;204:273-283.
153. Jankovic D, Kugler DG, Sher A. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol 2010;3:239-246.
154. Gao Q, et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005;37:584-592.
155. Langowski JL, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-465.